Formulary e-News:

Having trouble viewing this email? View in a browser.

You are subscribed to %%list.name%% as %%emailaddr%%. Unsubscribe.

Subscribe Now

to Formulary e-News
Formulary, A peer-reviewed drug management journal for managed care and hospital decision-makers
Part of the Modern Medicine Network

e-News

FormularyJournal.com

March 11, 2011
Formulary
Home Medication Safety FDA Actions Latest News Policy Watch Drug Watch
In This Issue
FDA updates pregnancy section of antipsychotic drug labels
Coadministration of flu, pneumococcal vaccines linked to febrile seizures
FDA to remove unapproved cough, cold, allergy meds
Opioid use in pregnant women and risk of birth defects
Monthly liver enzyme tests not needed for PAH drug
Bevacizumab could save premature infants' eyesight
Bevacizumab link to treatment-related death
in cancer patients

Survey
This month we would like to know...

Do you support The Preserving Access to Life-Saving Medicines Act, which would increase FDA's authority to prevent prescription drug shortages?

• Yes


• No

Click Here to Vote

Digital Edition
Formulary Digital Edition View Current Edition Subscribe to the Digital Edition

Labeling change for antipsychotic drugs highlights risk to newborns

FDA has updated the pregnancy section of drug labels for the entire class of antipsychotic medications to provide more information about the potential risk of extrapyramidal signs and withdrawal symptoms in newborns whose mothers take antipsychotics during the third trimester of pregnancy. Read full article.
divider

Coadministration of flu, pneumococcal vaccine increases febrile seizure risk

Children aged 6 to 23 months who receive trivalent inactivated flu vaccine concurrently with the 13-valent pneumococcal conjugate vaccine are at increased risk of febrile seizures, according to researchers at the Centers for Disease Control and Prevention in Atlanta and Harvard Medical School in Boston. Read full article.
divider

FDA to remove unapproved cough, cold, and allergy drugs from market

FDA recently announced its plans to remove certain unapproved prescription medicines used to treat cough, cold, and allergy symptoms. Read full article.

divider

Opioid use in pregnant women is linked to higher risk of birth defects

The risk of certain birth defects is higher in women given opioid analgesics such as hydrocodone during pregnancy, according to a new study. Read full article.

divider

FDA: Monthly liver enzyme tests no longer needed for PAH drug

FDA has approved a change to the prescribing information for ambrisentan 5-mg and 10-mg tablets (Letairis, Gilead Sciences) once-daily treatment to improve exercise ability and delay clinical worsening in patients with pulmonary arterial hypertension (PAH, WHO Group 1) and predominantly WHO Functional Class II-III symptoms. Read full article.

divider

Cancer drug may save sight of premature infants

The anticancer drug bevacizumab could help prevent babies with retinopathy of prematurity from becoming blind, reports a new study from the University of Texas Health Science Center at Houston Medical School. Read full article.

divider

Bevacizumab implicated in treatment-related death in cancer patients

The angiogenesis inhibitor bevacizumab, used with chemotherapy or biological therapy, carries an increased risk of treatment-related death in cancer patients compared with chemotherapy alone, a new study shows. Read full article.

divider

Top 5 Web Stories

  1. Dabigatran: A new orally available anticoagulant for prevention of strokes and thrombosis in patients with atrial fibrillation

  2. Contraceptive treatments: A review of current hormone options and newer agents for women

  3. Study finds different opioids offer variable safety in older adults with noncancer pain

  4. Dabigatran may be a cost-effective alternative to warfarin for stroke prevention in atrial fibrillation

  5. Risedronate sodium delayed-release tablets (Atelvia): A once-weekly oral bisphosphonate
divider

Contact Us

Contact a Formulary editor Click Here
Contact a Formulary sales representative Click Here
Learn about direct mail, reprints and classifieds in Formulary Click Here

You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.

To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.

Advanstar Healthcare

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or
fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.